D. Dalton / P. Kelly. have made several claims that aren't factual, looks as done intently; starting with the LinkedIn post June 29th, Capital Deck, Joint Press Release July 1st, SENDS Technology posted as Patented; when it has Patent Pending Status which legally, belongs to Landrace Bioscience Inc; PR marketing Language is usually looked at as forward-looking Puffery; making concrete, false assertions about regulated assets completely alters the legal landscape: University of Maryland School of Pharmacy has been falsely brought in as an official institutional research partnership, and joint product validation.
Direct written correspondence from Dr. Stephen Hoag (University of Maryland School of Pharmacy) clarifies that work performed was strictly on a transactional "fee-for-service" basis. Dr. Hoag explicitly stated that as a state agency, UMD does not endorse commercial products, and that expanded joint project discussions were unexecuted preliminary talks. Converting basic, transactional vendor testing into a broad "institutional academic partnership" demonstrates a deliberate choice to misrepresent routine contract testing as an official university endorsement to potential investors.
Publishing specific technical timeline benchmarks on the website; (such as "24-month stability"
without providing active FDA filings or backing clinical data indicates an affirmative effort to manufacture the appearance of commercial readiness.
Public Assertions; Major operational capabilities, partnerships, and commercial pipelines are heavily promoted across public marketing channels and press releases. These material operational claims and agreements were omitted from standard SEC and OTC quarterly filings (such as UNVC's Q2 report). Promoting unverified strategic claims on marketing distribution networks while omitting them from regulated financial reports shows an awareness of filing requirements and a deliberate decision to avoid regulatory reporting scrutiny.
It has begun; Following public exposure and regulatory submission of these misrepresentations, sequential site modifications on 11threetech.com provide direct evidence of post-scrutiny alterations: Early public site layouts prominently featured official faculty profile blocks, including Dr. Stephen Hoag, PhD, labeled as "Scientific Advisor" to imply direct institutional scientific backing from the University of Maryland School of Pharmacy. Following formal inquiries, these faculty profile blocks were completely removed from the live digital portal.
Original 5-Step Pipeline; Promoted an end-to-end commercial pathway linking API Selection--SENDS Formulation--Remy cGMP Manufacturing--Univec eDRLS / NDC--DispenseDoc Clinic Billing. Scrubbed to 4-step Pipeline; "DispenseDoc Clinic Billing" and point-of-care e-prescribing billing workflows were deleted.
Initial investor communications and press releases marketed the product as an FDA-approvable e-prescribing asset backed by "patented SENDS™ technology". The underlying offering represents an over-the-counter (OTC) topical pain patch. The Lidocaine 5% + Menthol 3% RX only presentation was quietly removed. Regulatory surveillance teams view the sequence as a deliberate effort to project commercial readiness to support share volume and price.
This post is irrelevant at this point: postal lady
postal lady
#178
Sep 17, 2026 at 6:44 AM
PL
Taken 09/14
Taken today;
Taken 08/28-Missing;
Taken 09/02 Missing;
Taken 09/01 Missing;
Taken 09/27
Direct written correspondence from Dr. Stephen Hoag (University of Maryland School of Pharmacy) clarifies that work performed was strictly on a transactional "fee-for-service" basis. Dr. Hoag explicitly stated that as a state agency, UMD does not endorse commercial products, and that expanded joint project discussions were unexecuted preliminary talks. Converting basic, transactional vendor testing into a broad "institutional academic partnership" demonstrates a deliberate choice to misrepresent routine contract testing as an official university endorsement to potential investors.
Publishing specific technical timeline benchmarks on the website; (such as "24-month stability"
without providing active FDA filings or backing clinical data indicates an affirmative effort to manufacture the appearance of commercial readiness. Public Assertions; Major operational capabilities, partnerships, and commercial pipelines are heavily promoted across public marketing channels and press releases. These material operational claims and agreements were omitted from standard SEC and OTC quarterly filings (such as UNVC's Q2 report). Promoting unverified strategic claims on marketing distribution networks while omitting them from regulated financial reports shows an awareness of filing requirements and a deliberate decision to avoid regulatory reporting scrutiny.
It has begun; Following public exposure and regulatory submission of these misrepresentations, sequential site modifications on 11threetech.com provide direct evidence of post-scrutiny alterations: Early public site layouts prominently featured official faculty profile blocks, including Dr. Stephen Hoag, PhD, labeled as "Scientific Advisor" to imply direct institutional scientific backing from the University of Maryland School of Pharmacy. Following formal inquiries, these faculty profile blocks were completely removed from the live digital portal.
Original 5-Step Pipeline; Promoted an end-to-end commercial pathway linking API Selection--SENDS Formulation--Remy cGMP Manufacturing--Univec eDRLS / NDC--DispenseDoc Clinic Billing. Scrubbed to 4-step Pipeline; "DispenseDoc Clinic Billing" and point-of-care e-prescribing billing workflows were deleted.
Initial investor communications and press releases marketed the product as an FDA-approvable e-prescribing asset backed by "patented SENDS™ technology". The underlying offering represents an over-the-counter (OTC) topical pain patch. The Lidocaine 5% + Menthol 3% RX only presentation was quietly removed. Regulatory surveillance teams view the sequence as a deliberate effort to project commercial readiness to support share volume and price.
This post is irrelevant at this point: postal lady
postal lady
#178
Sep 17, 2026 at 6:44 AM
PL
Taken 09/14
Taken today;
Taken 08/28-Missing;
Taken 09/02 Missing;
Taken 09/01 Missing;
Taken 09/27
1
